Cryo‑EM CRO Baiaode Secures ¥200 Million Series B to Scale Drug Discovery Platform

Why It Matters

The infusion of $28 million into Baiaode underscores the strategic shift toward cryo‑EM–based drug discovery, a technology that can unlock targets previously deemed undruggable. By expanding its platform and building extensive target libraries, Baiaode not only strengthens its competitive moat but also provides biotech firms with faster, more cost‑effective routes to lead identification, potentially compressing the preclinical timeline. For the broader CRO ecosystem, Baiaode’s raise signals heightened investor appetite for niche, high‑tech service providers that can deliver integrated, end‑to‑end solutions. As pharmaceutical pipelines increasingly rely on structural insights, CROs that combine protein production, X‑ray, and cryo‑EM capabilities are poised to become indispensable partners, reshaping the economics of early‑stage drug development.

Key Takeaways

• Baiaode closed a ¥200 million ($28 million) Series B round led by Kangjun Capital and Junlian Capital.
• Funding will support additional Titan Krios cryo‑EM instruments and expand protein‑production and structural‑biology teams.
• The company has delivered nearly 100 cryo‑EM structures with a best resolution of 2.1 Å.
• Baiaode serves over 200 clients worldwide, with 90 % of revenue from overseas markets.
• The “千靶万苗®” plan aims to create libraries of 1,000+ target structures and lead compounds within three years.

Pulse Analysis

Baiaode’s Series B raise arrives at a pivotal moment for structural biology services. Over the past five years, cryo‑EM has transitioned from a niche academic tool to a mainstream drug‑discovery platform, driven by breakthroughs in detector technology and automated data processing. This technological maturation has lowered barriers to entry, yet the capital intensity of high‑end microscopes—each costing upwards of $5 million—remains a gatekeeper. By securing $28 million, Baiaode can not only acquire additional instruments but also invest in the talent pipeline needed to operate them at scale, a dual advantage that many smaller CROs lack.

The competitive landscape is thin but fierce. Global players like Virogen and Proteros have long held the premium cryo‑EM market, but Baiaode’s integrated service—from gene cloning to structure determination—offers a one‑stop shop that reduces hand‑off risk and accelerates timelines. This model aligns with the growing trend of biotech firms outsourcing more of their early‑stage R&D to specialist providers, allowing them to focus on downstream development and commercialization. As a result, Baiaode’s expanded capacity could attract larger, multinational clients seeking to de‑risk their discovery programs.

Looking forward, the success of the “千靶万苗®” initiative will be a litmus test for Baiaode’s ability to translate infrastructure investment into tangible pipeline assets. If the company can populate its target and lead‑compound libraries as promised, it will create a defensible data moat that not only fuels its own growth but also locks in long‑term partnership contracts. In a market where speed to insight is increasingly synonymous with competitive advantage, Baiaode’s capital raise positions it to become a cornerstone of the next wave of structure‑guided therapeutics.